AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06325891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric mucosal brushing
Description: Gastric mucosal brushing will be performed at body of stomach in control group and non-tumorous area of body in gastric cancer group. If gastric body area could not feasible (eg. tumor involvement), then gastric antrum and more proximal part of body will be sampling.
Study NCT06325891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric mucosal biopsy
Description: Gastric mucosal biopsy will be performed at the area within 2 cm. from brushing site.
Study NCT05893862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: Oral Tablet
Study NCT05893862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral Tablet
Study NCT05893862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet
Study NCT06410651 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nimotuzumab with chemoradiotherapy
Description: Radiotherapy, 40-50.4Gy/20-28f. Nimotuzumab 400mg, ivgtt, W2d. Chemotherapy, S-1, 40-60mg/m2, on BSA，orally twice daily on radiotherapy days.
Study NCT05210439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-treatment of any active antibiotic regimen
Description: 7 days of any active antibiotic treatment for BSI-PA
Study NCT05210439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long-treatment of any active antibiotic regimen
Description: 14 days of any active antibiotic treatment for BSI-PA
Study NCT04751760 — intervention group
Intervention type: BIOLOGICAL
Intervention: collection of blood and urine
Description: blood and urine will be collected during a blood test scheduled for the follow-up of the patient
Study NCT05208996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: siCoV/KK46
Description: The modified phase I 3 + 1+1 study design was used in dose escalation from low dose to high dose to determine the maximum daily dose. Sequential assignment of Patient cohorts to one of three dose levels of inhaled siCoV/KK46: 3.7 mg, 11.1 mg, 22.2 mg.
Study NCT06331390 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: nothing
Study NCT05252741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: serum samples and punch skin biopsies
Description: we will take serum samples from psoriasis patients and healthy controls and skin punch biopsies from lesional and non-lesional areas in psoriasis patients.
Study NCT05252741 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: serum samples and punch skin biopsies
Description: we will take serum samples from psoriasis patients and healthy controls and skin punch biopsies from lesional and non-lesional areas in psoriasis patients.
Study NCT03705598 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Light physical exercise
Description: One hour each session, two sessions each week, for 24 weeks. Each session will be structured into three 15-minute segments (including warm-up activities/balance exercise/walking, upper and lower body strength exercise/walking, and stretching exercise/balance exercise/walking, respectively), each ending with a short break to record the Borg Rating of Perceived Exertion (RPE), followed by a 5-minute break time or cool-down/wrap-up session. The session will be taught by a certified exercise physiologist and a research assistant.
Study NCT03705598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi
Description: One hour each session, two sessions each week, for 24 weeks. Each session will be structured into three 15-minute segments (including warm-up activities/balance exercise/breathing exercise, Tai Chi walking drills, and Tai Chi 8-form, respectively), each ending with a short break to record the RPE, and followed by a 5-minute break or cool-down/wrap-up session. The session will be taught by an experienced Tai Chi instructor and a research assistant.
Study NCT05892705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: intrathecal injection of 5 mcg dexmedetomidine
Study NCT05892705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: intrathecal injection of 5 mcg dexmedetomidine
Study NCT06311058 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Description: 25g of whey protein isolate
Study NCT06311058 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein + BAA
Description: * Protein drink - 25g of whey protein isolate~* Amino Acid Blend - 7g of protein (4g Leucine, 1g iso leucine, 1g valine, 1g arginine)
Study NCT06311058 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: • isocaloric-matched (25g) maltodextrin supplement
Study NCT05316064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: probiotic
Description: oral administration of probiotic at 9 log CFU/day for 12 weeks to reduce vaginal abundance of HPV in women compared to placebo via the use of vaginal self-swab.
Study NCT05316064 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration of primarily carrier without the probiotic for 12 weeks
Study NCT05852093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib+Buprenorphine Transdermal Patch
Description: NSAIDs+narcotic analgesics
Study NCT05852093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib+Buprenorphine Transdermal Patch+Tizanidine
Description: NSAIDs+narcotic analgesics+Skeletal Muscle Relaxant
Study NCT05311826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD PHYSIOTHERAPY TREATMENT
Description: The standard postoperative rehabilitation process starts from the first postoperative day. Two sessions are provided daily, with the exception of Sunday and Saturday afternoon. A single physiotherapy session, lasting 30 minutes, can include bed exercises for upper and lower limbs and recovery of autonomy (sitting position, standing and ambulation). In this phase, the sessions are characterized by educational and counseling activities.~The patient will be encouraged to carry out the activities independently.
Study NCT05311826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EXPERIMENTAL diaphragmatic breathing exercise
Description: The subjects in the intervention group (EXP) will receive, in addition to standard physiotherapy treatment, diaphragmatic breathing exercise. Four exercises in different position (supine and side lying) will be provided for each physiotherapy session by a senior physiotherapist. Patients will be instructed to perform the same exercises independently to achieve relaxation and relief of pain symptoms.
Study NCT04608331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml) and dexmedetomidine (1.25 microgram/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
Study NCT04608331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
Study NCT05104203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracolumbar Interfascial Plane block
Description: Interfascial block done by injection between m. multifidus and m. longissimus
Study NCT05104203 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracolumbar Interfascial Plane block
Description: Interfascial block done by injection between m. multifidus and m. longissimus
Study NCT05104203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Thorcolumbar Interfascial Plane block
Description: Injection of local anesthetics between m. longissimus and m. illiocostalis
Study NCT05104203 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Thorcolumbar Interfascial Plane block
Description: Injection of local anesthetics between m. longissimus and m. illiocostalis
Study NCT06378684 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Group 1: JW0104(Period 1), C2207(Period 2), JW0104 + C2207(Period 3)
Description: Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
Study NCT06378684 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Group 2: JW0104 + C2207(Period 1), JW0104(Period 2), C2207(Period 3)
Description: Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
Study NCT06378684 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Group 3: C2207(Period 1), JW0104 + C2207(Period 2), JW0104(Period 3)
Description: Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
Study NCT06378684 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Group 4: JW0104(Period 1), JW0104 + C2207(Period 2), C2207(Period 3)
Description: Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
Study NCT06378684 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Group 5: JW0104 + C2207(Period 1), C2207(Period 2), JW0104(Period 3)
Description: Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
Study NCT06378684 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Group 6: C2207(Period 1), JW0104(Period 2), JW0104 + C2207(Period 3)
Description: Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
Study NCT05701878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMARTest mobile app for COVID-19 self-testing
Description: The mobile app has self-testing features and information with regard to self-testing and COVID-19.
Study NCT05905159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABM
Description: Direct attention away from pain-related information (i.e., facial expressions) through implicit training procedures
Study NCT05905159 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Direct attention equally towards pain-related and neutral information (i.e., facial expressions) through implicit training procedures
Study NCT06607900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hUC-MSC-sEV-001 nasal drops
Description: hUC-MSC-sEV-001 nasal drops
Study NCT05401721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum copeptin
Description: Blood test
Study NCT06064019 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nevisense
Description: The Nevisense system is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Since skin tissues have different electrical properties depending on cell structure and medical conditions, the resulting electrical impedance spectra will reflect the properties of the skin tissue.
Study NCT05842499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Line Set Strategy
Description: Substrate-guided ablation procedure of atypical atrial flutter
Study NCT05842499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional strategy
Description: Electrical activation-guided ablation
Study NCT05701982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Every Step Counts-Tai Chi
Description: The intervention is ESC-TC which is a web-based platform (Every Step Counts) to promote walking combined with pain management content, an online Tai Chi video library, and synchronous Tai Chi classes led by an instructor via teleconference. The intervention is delivered remotely.
Study NCT05701982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study NCT06306469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation practice
Description: physical and breathing exercises
Study NCT05639608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCALING
Description: SCALING WILL BE DONE AT BASELINE IN TEST GROUP.
Study NCT04990362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate oil, Mediterranean Diet
Description: Dietary Supplement: Pomegranate oil in a glass bottle of 0.15ml per day +Mediterranean dietary protocol Dietary Supplement: Mediterranean dietary protocol
Study NCT04990362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: Dietary Supplement: Mediterranean dietary protocol
Study NCT04622553 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mexiletine
Description: Patients will be enrolled sequentially into 2 cohorts.~Cohort 1 - (patients aged 12 to \< 18 years):~approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Cohort 2- (patients aged 6 to \< 12 years,):~approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period. Enrolment for Cohort 2 will begin after initial pharmacokinetics (PK), safety and efficacy are confirmed in this population, of patients in Cohort 1
Study NCT05715177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cura Kinesio-taping
Description: Cura tapes, a cotton strip with an acrylic adhesive. allows for unidirectional elasticity up to 60% beyond its resting length will be applied on origin to insertion on the superficial muscles of Quadriceps femoris (QF) (Vastus Medialis (VM), Vastus Lateralis (VL), Rectus Femoris (RF)
Study NCT05715177 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo kinesio-taping
Description: Placebo kinesiotaping
Study NCT06399562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: carbon-13 urea breath test (13C-UBT)
Description: The H. pylori infection was detected by carbon-13 urea breath test (13C-UBT), a delta over baseline (DOB) of ≥4.0 was considered positive for H. pylori, and a DOB\<4.0 was considered negative.
Study NCT06399562 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: The related factors of H. pylori infection were investigated by questionnaire survey. The physical examination population participated in the questionnaires of the physical examination center, which included basic demographic characteristics and living habits, and filled out the questionnaires on the use of serving chopsticks at the same time. In the community, members of each eligible family were asked to complete a questionnaire including the details such family general information, basic information of every family member, personal living habits, past medical history, and so on.
Study NCT04255758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle Ergometer Exercise
Description: 25 minutes, 70% VO2max steady state cycle ergometry exercise
Study NCT05716295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDK-703
Description: MDK-703 will be administered as specified under Arm description.
Study NCT05716295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint Inhibitor, Immune
Description: Checkpoint inhibitor will be administered as specified under Arm description.
Study NCT05662189 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-exendin-4
Description: 68Ga-exendin4 PET-CT scan
Study NCT05662189 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mixed meal test
Description: before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves
Study NCT04827979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daratumumab
Description: Daratumumab is a CD38 (Cluster of Differentiation 38)-directed cytolytic monoclonal antibody indicated for the treatment of multiple myeloma. In this study, daratumumab will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant.~Definition of highly sensitized: Potential kidney transplant recipients with either:~* calculated panel reactive antibodies (cPRA) ≥99.9% awaiting deceased donor transplant, or~* cPRA >98% (with >5 years of waiting time) awaiting living donor transplant
Study NCT04827979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: belatacept
Description: Belatacept, a monoclonal antibody, is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in subjects who have not received a kidney transplant.
Study NCT04827979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 12 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been >4 weeks since the previous bone marrow aspiration.
Study NCT05897242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone app
Description: Use ACT on Vaping smartphone app
Study NCT05897242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Receive text messages
Study NCT05897242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text Message
Description: Receive text messages
Study NCT05897242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05897242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06523959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 MG
Description: To evaluate the benefits and risks of thromboprophylaxis with oral factor Xa inhibitor Apixaban compared to No anticoagulation
Study NCT04853823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-APB
Description: PDC-APB Intra-muscular Injection
Study NCT04853823 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study NCT05074134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TNP-2092
Description: Subjects will receive a single intravenous (IV) dose of 300 mg/3 µCi \[14C\]-TNP-2092 administered over 60 minutes (± 10 minutes).
Study NCT06251141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gum Health gel
Description: Extraction of impacted mandibular third molars under local anaesthesia and irrigating the socket with normal saline, and filling the socket with the Gum Health gel
Study NCT06251141 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gel foam
Description: Extraction of impacted mandibular third molars under local anaesthesia and irrigating the socket
Study NCT05468216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MovIn-Lessons group
Description: The MovIn-Lessons intervention will consist of infusing PA in math, English and natural sciences lessons in primary education. The movement will be integrated in the learning activities for at least 20 minutes per session, at different physical intensities.
Study NCT05717491 — intervention group
Intervention type: OTHER
Intervention: Biological analysis, Physical examination and Questionnaires
Description: Biological analysis, Physical examination and questionnaires will be performed for all patients of the main group.
Study NCT05717491 — intervention group
Intervention type: OTHER
Intervention: Physical examination and Questionnaires
Description: In addition to exams for the main group, there will be 2 additional examinations (bone densitometry and arterial stiffness) for the patients of the subgroup and others questionnaires.
Study NCT06118580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol (Ethanol)
Description: 95% Ethanol diluted in Grape-flavored drink
Study NCT06118580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Grape-flavored drink
Study NCT05187429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML [Opdivo]
Description: Cohort A: Dose escalation phase: Nivolumab will be administered intravenously as a single dose in the dose escalation phase.
Study NCT05187429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML [Opdivo]
Description: Cohort B: Randomisation phase: Nivolumab will be administered intravenously as a fixed single dose in the randomisation phase.
Study NCT05187429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Cohort B: Randomisation phase: Saline will be administered intravenously as a single dose in the randomisation arm.
Study NCT04722107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV2/8-hCYP4V2
Description: rAAV2/8-hCYP4V2 is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene
Study NCT05447143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue Severity Scale
Description: Evaluation for severity of fatigue
Study NCT05447143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fatigue Severity Scale
Description: Evaluation for severity of fatigue
Study NCT05447143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Berg Balance Test
Description: Evaluation of balance
Study NCT05447143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Berg Balance Test
Description: Evaluation of balance